301 related articles for article (PubMed ID: 26386320)
21. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.
Calmettes C; Vigouroux S; Labopin M; Tabrizi R; Turlure P; Lafarge X; Marit G; Pigneux A; Leguay T; Bouabdallah K; Dilhuydy MS; Duclos C; Mohr C; Lascaux A; Dumas PY; Dimicoli-Salazar S; Saint-Lézer A; Milpied N
Biol Blood Marrow Transplant; 2015 May; 21(5):860-5. PubMed ID: 25617807
[TBL] [Abstract][Full Text] [Related]
24. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
[TBL] [Abstract][Full Text] [Related]
25. Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience.
De Jong CN; Saes L; Klerk CPW; Van der Klift M; Cornelissen JJ; Broers AEC
PLoS One; 2017; 12(10):e0187184. PubMed ID: 29073260
[TBL] [Abstract][Full Text] [Related]
26. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease.
Yalniz FF; Hefazi M; McCullough K; Litzow MR; Hogan WJ; Wolf R; Alkhateeb H; Kansagra A; Damlaj M; Patnaik MM
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1478-1484. PubMed ID: 28495641
[TBL] [Abstract][Full Text] [Related]
28. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
29. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
30. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.
Meunier M; Bulabois CE; Thiebaut-Bertrand A; Itzykson R; Carre M; Carras S; Garban F; Cahn JY
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1451-4. PubMed ID: 24910381
[TBL] [Abstract][Full Text] [Related]
32. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
Front Immunol; 2021; 12():749266. PubMed ID: 34621279
[TBL] [Abstract][Full Text] [Related]
33. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.
von Dalowski F; Kramer M; Wermke M; Wehner R; Röllig C; Alakel N; Stölzel F; Parmentier S; Sockel K; Krech M; Schmitz M; Platzbecker U; Schetelig J; Bornhäuser M; von Bonin M
Stem Cells; 2016 Feb; 34(2):357-66. PubMed ID: 26418955
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
[TBL] [Abstract][Full Text] [Related]
36. Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form.
Rubegni P; Feci L; Poggiali S; Marotta G; D'Ascenzo G; Murdaca F; Fimiani M
Br J Dermatol; 2013 Aug; 169(2):450-7. PubMed ID: 23534380
[TBL] [Abstract][Full Text] [Related]
37. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
[TBL] [Abstract][Full Text] [Related]
38. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.
Danylesko I; Bukauskas A; Paulson M; Peceliunas V; Gedde-Dahl D Y T; Shimoni A; Shouval R; Griskevicius L; Floisand Y; Nagler A
Bone Marrow Transplant; 2019 Jul; 54(7):987-993. PubMed ID: 30356163
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
40. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
